Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fortress Biotech has the GF Score of 44, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Fortress Biotech
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Fortress Biotech (STU:CNB1) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Fortress Biotech GF Score Related Terms
STU:CNB1 vs RLYB, INO, SEER: GF Score Comparison
For the Biotechnology subindustry, Fortress Biotech's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech GF Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's GF Score distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's GF Score falls into.
Fortress Biotech (STU:CNB1) has a GF Score of 44 as of Jul. 21, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Fortress Biotech and its competitors. This is near median its historical median of 48.00. Over the past decade, Fortress Biotech's GF Score has ranged from 16.00 to 72.00.
Is Fortress Biotech's GF Score too high?
Fortress Biotech's current GF Score of 44 is near median its 10-year median of 48.00. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 72.00. Overall, Fortress Biotech has a GF Score™ of 44/100, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's GF Score compare to RLYB and INO?
Fortress Biotech's GF Score of 44 can be compared against companies in the Biotechnology industry. Historically, Fortress Biotech's own GF Score has ranged from 16.00 to 72.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Biotechnology company?
A good GF Score depends on the Biotechnology industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Fortress Biotech and its competitors. Fortress Biotech's current GF Score is 44, which is near median its own 10-year median of 48.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Fortress Biotech (STU:CNB1) has a current GF Score of 44. The stock's GF Value™ is €0.73, compared to a current price of €1.93 — trading 164.4% above its estimated fair value. The current GF Score is 44, which is near median its 10-year median of 48.00. Fortress Biotech's overall GF Score™ is 44/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Fortress Biotech (STU:CNB1), the current GF Score is 44 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (STU:CNB1) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of €1.93 is trading 164.4% above its estimated GF Value™ of €0.73.
Key valuation signals for STU:CNB1:
GF Score: 44 (near median its 10-year median of 48.00)
GF Value™: €0.73 vs. price of €1.93 (164.4% above fair value)
No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score
Get the complete analysis for STU:CNB1
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:CNB1 has been successfully added to your 
